{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T21:46:44Z","timestamp":1757540804377},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,6,28]],"date-time":"2002-06-28T00:00:00Z","timestamp":1025222400000},"content-version":"vor","delay-in-days":178,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Laboratory Analysis"],"published-print":{"date-parts":[[2002,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Many HIV patients develop a progressive syndrome of abnormal body fat distribution accompanied by hypertriglyceridemia. Antiretroviral agents are thought to be etiologic in the syndrome, often termed \u201chighly active antiretroviral therapy (HAART)\u2010associated lipodystrophy.\u201d In the course of clinical HIV genotype testing, we observed that our HIV patients with hypertriglyceridemia had viral genotypes that were more highly mutated than those of our therapy\u2010matched control patients. Hypertriglyceridemia was statistically associated with predicted resistance for three nucleoside reverse transcriptase inhibitors: zidovudine, abacavir, and stavudine. Statistical analysis of 51 patients in retrospect revealed a strong association of mutations at reverse transcriptase codons M41 and T215 with hypertriglyceridemia (chi\u2010square (\u03c7<jats:sup>2<\/jats:sup>) = 8.375, <jats:italic>P<\/jats:italic>=.0038; and \u03c7<jats:sup>2<\/jats:sup>=7.445, <jats:italic>P<\/jats:italic>=.0064, respectively). This was in contrast to silent mutations, which occurred at equivalent rates in retroviral genotypes of patients with and without hypertriglyceridemia. The findings imply that the HIV genotype itself may be a significant etiologic factor in antiretroviral\u2010associated lipodystrophy. \u00a9 2002 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jcla.10042","type":"journal-article","created":{"date-parts":[[2002,9,11]],"date-time":"2002-09-11T02:05:28Z","timestamp":1031709928000},"page":"202-208","source":"Crossref","is-referenced-by-count":5,"title":["Human immunodeficiency virus genotype and hypertriglyceridemia"],"prefix":"10.1002","volume":"16","author":[{"given":"Soni J.","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ferreira\u2010Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carleton T.","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,6,28]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"68","article-title":"Antiviral therapy\u2010associated lipodystrophy syndrome","volume":"40","author":"Anderson SJ","year":"2000","journal-title":"Clin Chem"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1310\/BRE5-448N-WUPU-JWVL"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2001.00057.x"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200104130-00008"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.77.3.158"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0953-6205(00)00103-5"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200112070-00007"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200110190-00020"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00126334-200107010-00005","article-title":"Association between insulin resistance and hepatitis C virus chronic infection in HIV\u2010hepatitis C virus\u2010coinfected patients undergoing antiretroviral therapy","volume":"27","author":"Duong M","year":"2001","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1999.00615.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/jinf.2001.0829"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200009080-00008"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200005050-00006"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200001070-00006"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00042560-200201010-00003","article-title":"Body habitus changes and metabolic alterations in protease inhibitor\u2010naive HIV\u20101\u2010infected patients treated with two nucleoside reverse transcriptase inhibitors","volume":"29","author":"Galli M","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/00002030-199909100-00009","article-title":"A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long\u2010term nucleoside analogue therapy","volume":"13","author":"Saint\u2010Marc T","year":"1999","journal-title":"AIDS"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200105040-00005"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2001.00073.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200107270-00008"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200008180-00019"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90225-8"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91058-G"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1182\/blood.V95.10.3191","article-title":"Alteration of tumor necrosis factor\u2010alpha T\u2010cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodficiency virus\u2010associated lipodystrophy syndrome","volume":"95","author":"Ledru E","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5394.1669"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.14.6410-6417.2001"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.2023"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200008180-00012"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7827(01)00019-4"}],"container-title":["Journal of Clinical Laboratory Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcla.10042","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcla.10042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T11:18:48Z","timestamp":1700392728000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcla.10042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1002\/jcla.10042"],"URL":"https:\/\/doi.org\/10.1002\/jcla.10042","archive":["Portico"],"relation":{},"ISSN":["0887-8013","1098-2825"],"issn-type":[{"value":"0887-8013","type":"print"},{"value":"1098-2825","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}